Canadian Phase 2 Trial • Health Canada Approved
HELPING UNDERDEVELOPED LUNGS WITH CELLS [HULC-2]
A new possibility
for the smallest lungs
Mesenchymal Stromal Cells in extreme preterm infants at risk of developing Bronchopulmonary Dysplasia – A Phase 2 Multi-Centre Open-Label Randomized Controlled Trial
The trial
HULC-2 is a Canadian clinical trial exploring a new treatment for extremely premature babies (born before 28 weeks of pregnancy). These babies are at risk of developing bronchopulmonary dysplasia (BPD), a serious lung condition that affects breathing and development.
This study is testing a treatment using special cells from donated umbilical cords, called umbilical cord-derived mesenchymal stromal cells (UC-MSCs), to see if they can safely improve lung health and reduce complications related to prematurity.
Purpose of the trial
The purpose of the HULC-2 trial is to determine whether UC-MSC therapy can safely reduce the number of days extremely premature babies need support from a breathing machine (called a ventilator) and improve their overall lung health. By comparing babies who receive UC-MSCs to those who do not, researchers aim to understand if this treatment can help prevent BPD and reduce other complications related to preterm birth.
01
Participating sites
0
Babies enrolled
0%
Entollement target met
0
Cells injected
